Kiora Pharmaceuticals
Develops intravitreal photoswitch and DHODH-inhibitor candidates for retinal degeneration and inflammation.
Something off on this page? Send us feedback.
Profile
Develops intravitreal small-molecule candidates for inherited retinal degeneration and retinal inflammation. Relies on license-related payments, partner reimbursements, potential milestones, and royalties rather than product sales.
Develops KIO-301, an intravitreal molecular photoswitch intended to make surviving retinal ganglion cells light-responsive after photoreceptor loss, and KIO-104, an intravitreal DHODH inhibitor for retinal inflammation and macular edema. Both candidates are in mid-stage clinical studies.
Operates from Encinitas and through offices and trial sites in Australia and Austria, while reporting one geographic segment. Its asset- and partnership-oriented model uses acquired technologies, outsources clinical work and manufacturing, and has licensed most non-Asian ophthalmic rights to KIO-301 to Théa Open Innovation.
Has no approved products or product sales. Its economics depend on upfront and option payments, reimbursed research costs, potential milestones, and royalties, while clinical execution depends on third-party manufacturers, CROs, medical institutions, investigators, and data-management providers.
Company facts
Key statistics
Year to date +27.7% · Average volume (30d) 17.9K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | −$0.47 | −$0.34 | +27.7% | — | — | — | +3.13% |
| May 8, 2026Q1 FY26 | −$0.71 | −$0.58 | +18.3% | $1.5M | — | — | −1.63% |
| Mar 25, 2026Q4 FY25 | −$0.67 | −$1.60 | −138.8% | $1.5M | — | — | −3.43% |
| Nov 7, 2025Q3 FY25 | −$0.72 | $0.01 | +101.4% | $750.0K | — | — | 0.00% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$42.0K | $0 | |
| Operating income | −$2.3M | −$2.4M | −$794.4K | −$7.3M | −$2.5M | −$2.2M | |
| Net income | −$2.2M | −$2.2M | $26.8K | −$6.5M | −$2.4M | −$2.1M | |
| Diluted EPS | −$0.52 | −$0.54 | $0.01 | −$1.59 | −$0.58 | −$0.34 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $16.0M · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $16.8M · Total debt $333.0K · Total assets $23.8M · Shareholders' equity $16.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 4.43M · Float 4.17M · 94.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 464.7K | 9.90% | 13G | Feb 11, 2026 |
| Perceptive Advisors LLC | 442.4K | 9.99% | 13G | Aug 10, 2026 |
| Nantahala Capital Management, LLC | 438.5K | 9.99% | 13G | May 15, 2026 |
| Alyeska Investment Group, L.P. | 394.7K | 9.99% | 13G | May 15, 2026 |
| ADAR1 Capital Management, LLC | 362.5K | 9.90% | 13G | Aug 14, 2025 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Ocugen
Broad RP gene therapy targets the same mutation-agnostic retinal-disease market.
- Regeneron
Anti-VEGF injection competes in the KIO-104 diabetic-macular-edema setting.
- AbbVie
Systemic, non-steroidal TNF blockade is an approved option for posterior NIU.
